With the goal of informing clinician practice, a new study explores the harms and benefits of continuing and of discontinuing the long-term prescription of opioid medicines to adults with chronic pain ...
On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
Chronic pain is complex and difficult to treat. Prescribing opioid pain medications has become controversial but may help ...
The US FDA has approved Journavx, a new pain reliever without the risks for addiction or overdose linked to drugs like Vicodin and OxyContin.
Advancements have been made in the pain management field that have successfully found FDA approved alternatives to ...
The apex drug regulatory authority has prohibited the production and export of all combinations of pain relief medicines tapentadol and carisoprodol, over news reports that unapproved combinations of ...
Vertex gets FDA approval for its non-opioid pain drug suzetrigine, the first new class of pain medicine in the US in more than 20 years.
WRIC Richmond on MSN2d
FDA approves first opioid-free painkiller in over two decadesThe U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...
2don MSNOpinion
One way to address the opioid crisis is to clear away red tape and make other pain treatments more easily available, Rep.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback